Suppr超能文献

用于检测高级别宫颈上皮内瘤变(CIN2+)的人乳头瘤病毒E6/E7信使核糖核酸检测:一项系统综述

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review.

作者信息

Derbie Awoke, Mekonnen Daniel, Woldeamanuel Yimtubezinash, Van Ostade Xaveer, Abebe Tamrat

机构信息

1Department of Medical Microbiology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

2Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.

出版信息

Infect Agent Cancer. 2020 Feb 7;15:9. doi: 10.1186/s13027-020-0278-x. eCollection 2020.

Abstract

BACKGROUND

Genital infection with certain types of Human papillomavirus (HPV) is a major cause of cervical cancer globally. For early detection of premalignant dysplasia, evidences are coming out on the usefulness of HPV E6/E7 mRNA test as a potential tool compared with cytology and HPV DNA testing. Taking into account shortage of compiled data on this field, the aim of this systematic review was to describe the latest diagnostic performance of HPV E6/E7 mRNA testing to detect high grade cervical lesions (CIN2+) where by histology was taken as a gold standard.

METHODS

Articles published in English were systematically searched using key words from PubMed/Medline and SCOPUS. In addition, Google Scholar and the Google database were searched manually for grey literature. Two reviewers independently assessed study eligibility, risk of bias and extracted the data. We performed a descriptive presentation of the performance of E6/E7 mRNA test (in terms of sensitivity, specificity, negative and positive predictive values) for the detection of CIN2 + .

RESULTS

Out of 231 applicable citations, we have included 29 articles that included a total of 23,576 study participants (age range, 15-84 years) who had different cervical pathologies. Among the participants who had cervical histology, the proportion of CIN2+ was between 10.6 and 90.6%. Using histology as a gold standard, 11 studies evaluated the PreTect HPV Proofer, 7 studies evaluated the APTIMA HPV assay (Gen-Probe) and 6 studies evaluated the Quantivirus® HPV assay. The diagnostic performance of these three most common mRNA testing tools to detect CIN2+ was; 1) PreTect Proofer; median sensitivity 83%, specificity 73%, PPV 70 and NPV 88.9%. 2) APTIMA assay; median sensitivity 91.4%, specificity 46.2%, PPV 34.3% and NPV 96.3%. 3) Quantivirus®: median sensitivity 86.1%, specificity 54.6%, PPV 54.3% and NPV was at 89.3%. Further, the area under the receiver operating characteristics (AU-ROC) curve varied between 63.8 and 90.9%.

CONCLUSIONS

The reported diagnostic accuracy implies that HPV mRNA based tests possess diagnostic relevance to detect CIN2+ and could potentially be considered in areas where there is no histology facility. Further studies including its cost should be considered.

摘要

背景

感染某些类型的人乳头瘤病毒(HPV)是全球宫颈癌的主要病因。对于癌前发育异常的早期检测,与细胞学检查和HPV DNA检测相比,HPV E6/E7 mRNA检测作为一种潜在工具的有效性证据正在不断涌现。考虑到该领域汇编数据的短缺,本系统评价的目的是描述以组织学为金标准时,HPV E6/E7 mRNA检测在检测高级别宫颈病变(CIN2+)方面的最新诊断性能。

方法

使用来自PubMed/Medline和SCOPUS的关键词对英文发表的文章进行系统检索。此外,还手动在谷歌学术和谷歌数据库中搜索灰色文献。两名评审员独立评估研究的合格性、偏倚风险并提取数据。我们对E6/E7 mRNA检测在检测CIN2+方面的性能(敏感性、特异性、阴性和阳性预测值)进行了描述性呈现。

结果

在231篇适用的引文中,我们纳入了29篇文章,这些文章共包括23576名研究参与者(年龄范围15 - 84岁),他们患有不同的宫颈病变。在进行宫颈组织学检查的参与者中,CIN2+的比例在10.6%至90.6%之间。以组织学为金标准,11项研究评估了PreTect HPV Proofer,7项研究评估了APTIMA HPV检测(Gen - Probe),6项研究评估了Quantivirus® HPV检测。这三种最常用的mRNA检测工具检测CIN2+的诊断性能如下:1)PreTect Proofer;中位敏感性83%,特异性73%,阳性预测值70,阴性预测值88.9%。2)APTIMA检测;中位敏感性91.4%,特异性46.2%,阳性预测值34.3%,阴性预测值96.3%。3)Quantivirus®:中位敏感性86.1%,特异性54.6%,阳性预测值54.3%,阴性预测值为89.3%。此外,受试者工作特征曲线(AU - ROC)下的面积在63.8%至90.9%之间。

结论

报告的诊断准确性表明,基于HPV mRNA的检测对于检测CIN2+具有诊断相关性,并且在没有组织学检测设施的地区可能会被考虑使用。应考虑包括其成本在内的进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c0/7006188/ad819bc3d9c6/13027_2020_278_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验